A novel capecitabine schedule (7 on—7 off) is feasible with lapatinib for patients with HER2-positive metastatic breast cancer refractory to trastuzumab Meeting Abstract


Authors: Gajria, D.; Theodoulou, M.; Feigin, K.; Patil, S.; Geneus, S.; Drullinsky, P.; D'Andrea, G.; Lake, D.; Norton, L.; Hudis, C.; Traina, T. A.
Abstract Title: A novel capecitabine schedule (7 on—7 off) is feasible with lapatinib for patients with HER2-positive metastatic breast cancer refractory to trastuzumab
Meeting Title: 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS)
Journal Title: Cancer Research
Volume: 70
Issue: 24 Suppl.
Meeting Dates: 2010 Dec 9-12
Meeting Location: San Antonio, TX
ISSN: 0008-5472
Publisher: American Association for Cancer Research  
Date Published: 2010-12-15
Language: English
ACCESSION: WOS:000209695800289
DOI: 10.1158/0008-5472.sabcs10-p6-11-12
PROVIDER: wos
Notes: Meeting Abstract: P6-11-12 -- Source: Wos
Altmetric Score
MSK Authors
  1. Kimberly Nicole Feigin
    18 Feigin
  2. Sujata Patil
    365 Patil
  3. Clifford Hudis
    818 Hudis
  4. Larry Norton
    544 Norton
  5. Diana E Lake
    69 Lake
  6. Devika Gajria
    22 Gajria
  7. Tiffany A Traina
    145 Traina
  8. Stephanie Geneus
    6 Geneus